South Dakota Investment Council Acquires 22,900 Shares of Progyny, Inc. $PGNY

South Dakota Investment Council raised its holdings in Progyny, Inc. (NASDAQ:PGNY) by 20.0% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 137,524 shares of the company’s stock after acquiring an additional 22,900 shares during the quarter. South Dakota Investment Council owned about 0.18% of Progyny worth $2,335,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of PGNY. State Street Corp lifted its stake in shares of Progyny by 1.5% in the 4th quarter. State Street Corp now owns 2,953,186 shares of the company’s stock valued at $75,838,000 after purchasing an additional 44,642 shares during the period. Fort Washington Investment Advisors Inc. OH boosted its position in shares of Progyny by 46.9% in the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company’s stock worth $45,734,000 after purchasing an additional 859,289 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Progyny by 260.9% during the fourth quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock worth $57,607,000 after purchasing an additional 1,621,688 shares during the period. Ameriprise Financial Inc. grew its stake in shares of Progyny by 37.6% during the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock worth $43,933,000 after purchasing an additional 545,431 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Progyny by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 1,972,219 shares of the company’s stock valued at $50,655,000 after purchasing an additional 20,533 shares during the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Progyny Stock Down 1.1%

Shares of PGNY stock opened at $31.13 on Friday. Progyny, Inc. has a 12-month low of $16.10 and a 12-month high of $33.06. The firm has a market capitalization of $2.44 billion, a price-to-earnings ratio of 40.43, a price-to-earnings-growth ratio of 2.50 and a beta of 1.01. The firm has a fifty day moving average of $28.55 and a 200-day moving average of $23.26.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.50 EPS for the quarter, topping the consensus estimate of $0.26 by $0.24. The business had revenue of $328.50 million for the quarter, compared to the consensus estimate of $326.46 million. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The firm’s revenue was down 26.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.17 EPS. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Research analysts expect that Progyny, Inc. will post 1.19 earnings per share for the current year.

Progyny announced that its Board of Directors has approved a stock repurchase program on Tuesday, May 26th that authorizes the company to buyback $200.00 million in outstanding shares. This buyback authorization authorizes the company to repurchase up to 10.3% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board believes its stock is undervalued.

Insider Buying and Selling

In other news, insider Geoffrey Clapp sold 1,530 shares of Progyny stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $25.58, for a total transaction of $39,137.40. Following the transaction, the insider owned 59,117 shares in the company, valued at $1,512,212.86. The trade was a 2.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Mark S. Livingston sold 2,517 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $25.50, for a total value of $64,183.50. Following the completion of the transaction, the chief financial officer owned 74,688 shares of the company’s stock, valued at $1,904,544. This represents a 3.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 36,916 shares of company stock valued at $939,875. 9.90% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. BTIG Research increased their target price on Progyny from $30.00 to $40.00 and gave the company a “buy” rating in a research note on Friday, July 24th. Truist Financial boosted their target price on Progyny from $30.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday, June 22nd. KeyCorp upped their price target on Progyny from $30.00 to $35.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Wall Street Zen cut Progyny from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 25th. Finally, Leerink Partners set a $38.00 price target on shares of Progyny in a research report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $33.25.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.